capecitabine has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Badawy, O; Eldin, AS; Fakhry, H; Hassan, EA; Hetta, HF; Rayan, A; Soliman, A; Zahran, AM | 1 |
| Bearz, A; Berretta, M; Di Benedetto, F; Lleshi, A; Spina, M; Tirelli, U | 1 |
2 other study(ies) available for capecitabine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Case-Control Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis A Virus Cellular Receptor 2; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Programmed Cell Death 1 Receptor; Receptors, CCR5; Sorafenib; Survival Rate; T-Lymphocytes | 2020 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2006 |